Immunovant Inc. Common Stock vs Range Nuclear Renaissance ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B), while Range Nuclear Renaissance ETF trades at $61.26 (market cap $698.21M). The key difference: Immunovant Inc. Common Stock is far larger — about 9× Range Nuclear Renaissance ETF's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Range Nuclear Renaissance ETF for 18 Days on average.
| IMVT | NUKZ | |
|---|---|---|
Market Cap | $6.25B | $698.21M |
Volume | 1,755,411 | 57,444 |
Sector | Health | Sector/Thematic |
52-Week High | $44.96 | $76.23 |
52-Week Low | $17.03 | $60.23 |
Typical Hold Time | 1 Days | 18 Days |
Enterprise Value | $5.35B | — |
Trailing returns across standard periods
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →